Unlocking Value: 10 Must-Research Stocks
Value Radar: 10 Fresh Ideas + Full Valuation Deep‑Dive on 3M (MMM)
Date: February 5, 2026 (United States)
Market anchor: The U.S. 10‑year Treasury yield has printed 4.24%–4.29% this week; we use 4.26% as the risk‑free rate. Federal Reserve H.15, February 4, 2026. (investors.3m.com)
1) Ten value‑based candidates to research now
Screen: resilient free cash flow, clear self‑help levers, balance‑sheet discipline, and a discount to conservative intrinsic value. These are new vs. prior editions.
- 3M (MMM) — post‑Solventum spin industrial with improving margins, >$4B adjusted FCF in 2025, and updated 2026 guidance; legacy legal overhang largely quantified. (investors.3m.com)
- Keurig Dr Pepper (KDP) — energy‑drink acquisition (GHOST) boosting mix; reaffirmed high‑single‑digit EPS growth in 2025. (investopedia.com)
- FedEx (FDX) — DRIVE cost‑out and air/surface network optimization continue to widen the gap vs. peers in an improving parcel/pricing setup. (investopedia.com)
- State Street (STT) — operating leverage to higher for‑longer cash yields and fee stabilization; watch flows and buybacks. (marketwatch.com)
- Baxter (BAX) — portfolio cleanup with Vantive spin and margin rebuild; deleveraging path is key. (investors.3m.com)
- Zimmer Biomet (ZBH) — procedure volumes resilient; steady margin/FCF improvement through productivity programs. (investors.3m.com)
- T. Rowe Price (TROW) — potential product/flows catalyst via strategic tie‑ups; sensitivity to markets remains. (ft.com)
- Unilever (UL) — execution under new leadership with margin discipline and simplification; a classic staples cash engine. (investopedia.com)
- Smurfit WestRock (SW) — newly combined paper/packaging leader; global scale and synergy capture drive cash returns. (ir.westrock.com)
- Whirlpool (WHR) — deep cyclicality but strong cost actions and cash discipline into a potential U.S. housing refresh. (ir.westrock.com)
Pick for the deep dive below: 3M (not previously covered in our full valuation).
2) Deep Dive: 3M (MMM)
2.1 What the business is today
- Post spin-off of its health care arm (Solventum) on April 1, 2024, 3M is a focused industrial supplier across Safety & Industrial, Transportation & Electronics, and Consumer. Management is rebuilding growth and margins with the “3M eXcellence” operating system. (news.3m.com)
- 2025 results: adjusted sales $24.3B (+2.7% y/y), adjusted operating margin 23.4% (+200 bps), adjusted EPS $8.06 (+10% y/y), adjusted FCF $4.4B. 2026 guide: ~4% adjusted sales growth, +70–80 bps margin expansion, and adjusted EPS $8.50–$8.70 with $5.6–$5.8B operating cash flow. (investors.3m.com)
- Dividend reset and trajectory: after the 2024 reset post‑spin, the board raised the quarterly dividend to $0.78 for Q1‑26. (barrons.com)
- Legal overhang materially quantified:
- PFAS public water systems settlement (final approval Mar 29, 2024) with a present‑value commitment up to ~$10.3B over 13 years. 3M is also exiting PFAS manufacturing by end‑2025. (investors.3m.com)
- Combat Arms earplug litigation settlement up to $6.0B (cash basis after Jan‑24 amendment), with participation exceeding thresholds and >99% of claims expected to resolve; insurance recoveries are being pursued. (investors.3m.com)
Why it screens as value‑oriented now
- Fundamentals are mending (FCF, margins, growth), management laid out a medium‑term plan to reach ~25% operating margin by 2027, and litigation cash flows are scheduled and reserved—reducing tail risk. (investors.3m.com)
2.2 Balance sheet, cash, and share base
- Net debt stepped up through 2025 on settlement payments and buybacks, but remains manageable: Sep 30, 2025 net debt was ~$7.4B (total debt $12.6B, cash/marketable $5.2B). (investors.3m.com)
- Shares outstanding were ~539.5M at Dec 31, 2024; the company returned $4.8B to shareholders in 2025 via dividends and repurchases (reducing share count modestly). We model a diluted share range of ~525–540M. (investors.3m.com)
2.3 Business roadmap and the competitive set
- 3M plans to “outperform macro” on organic growth, expand operating margin to ~25% by 2027, and convert >100% of earnings to adjusted FCF, supported by a ~$1.0B capex cadence. (investors.3m.com)
- 2026 tariff/FX playbook: company reiterated mitigation steps and kept guidance despite headwinds. (marketwatch.com)
- Peers’ valuation context: high‑quality industrials often trade mid‑ to high‑teens EV/EBITDA (e.g., HON ~17x; EMR ~19x; ITW ~18x; PH ~20x). 3M should trade at a discount until execution/legacy risks fully clear. (valueinvesting.io)
3) Ground‑up valuation: FCFF DCF + comparables
We anchor to what 3M just delivered and guided, then build five‑year FCFF from first principles. All cash figures USD.
Key starting points and cross‑checks
- Base revenue: 2025 adjusted sales $24.3B. 2026 guide implies ~4% adjusted sales growth. (investors.3m.com)
- Margin path: 2025 adjusted operating margin 23.4%; medium‑term target ~25% by 2027 (we fade in). (investors.3m.com)
- D&A proxy: quarterly D&A was ~$290M in 1Q25 (≈$1.1–$1.2B annualized); we grow it modestly. (investors.3m.com)
- Capex: management indicated ~$0.9B–$1.1B for 2025; we assume ~$1.1B run‑rate beyond 2026. (investors.3m.com)
- Working capital: modeled neutral through the cycle.
- Risk‑free rate: 10‑year at 4.26% (Feb 4, 2026). Equity beta assumed ~1.1; equity risk premium 5.5%; after‑tax cost of debt ~5%. Base WACC 9.0% (bull 8.0%, bear 10.5%). (investors.3m.com)
3.1 FCFF model (2026–2030 explicit)
Assumptions (base case; “adjusted” excludes manufactured PFAS revenue per company reporting):
- Sales: 2026 $25.3B (+4%), 2027 $26.2B (+3.5%), 2028 $27.0B (+3%), 2029 $27.8B (+3%), 2030 $28.6B (+3%). (investors.3m.com)
- Operating margin: 24.1% (’26), 25.0% (’27), 25.2% (’28), 25.3% (’29), 25.5% (’30). Medium‑term aligns with ~25% target. (investors.3m.com)
- Tax rate: 22% effective.
- D&A: $1.1B (’26) rising to $1.25B (’30). (investors.3m.com)
- Capex: $1.1B annually. (investors.3m.com)
- Working capital: ~0 net over the horizon.
Implied FCFF (rounded):
- 2026: ~$4.8B
- 2027: ~$5.2B
- 2028: ~$5.4B
- 2029: ~$5.5B
- 2030: ~$5.7B
These FCFF levels reconcile against 2026 operating cash flow guidance of $5.6–$5.8B and >100% FCF conversion (our FCFF is after capex), providing an external check. (investors.3m.com)
Discounting at WACC 9.0% with a 2.0% terminal growth:
- PV(2026–2030 FCFF) ≈ $20.5B
- Terminal value = 2030 FCFF × (1+g) / (WACC−g) ≈ $83.6B; PV ≈ $54.4B
- Enterprise value (EV) ≈ $74.9B
Equity bridge:
- Less net debt: use Sep 30, 2025 net debt of ~$7.4B as conservative reference (legal payments/buybacks drove 2025 moves). (investors.3m.com)
- Equity value ≈ $67.5B
- Per‑share value: using 525–540M diluted shares, ≈ $125–$129 per share.
Sensitivity (per share):
- Bull (WACC 8.0%, g 2.25%, slightly faster margin lift): ≈ $155–$175.
- Bear (WACC 10.5%, g 1.5%, margins stall at ~24%): ≈ $95–$110.
Interpretation: at today’s ~$164 (Feb 5, 2026), shares trade above our base DCF and closer to a bullish set of assumptions.
3.2 Comparable multiples cross‑check
- Quality industrial peers currently trade near high‑teens EV/EBITDA (HON ~17x; EMR ~19x; ITW ~18x; PH ~20x). (valueinvesting.io)
- Normalized 3M EBITDA under our 2027–2028 base (EBIT margin ≈25% plus ~$1.1B–$1.2B D&A) is ≈$6.8–$7.3B. Applying a “discounted quality” multiple of 11–13x (to reflect residual litigation/perception risk) yields EV ≈ $75–$95B, implying equity ≈ $67–$87B, or ≈ $125–$165 per share (525–540M shares). (investors.3m.com)
DCF–comps triangulation: fair value clusters around ~$125–$145 with a wide band driven by discount rate, terminal growth, and how quickly 3M sustains ~25% operating margins.
4) Investment view and price map
- Verdict: solid industrial turnaround, but not a classic “value” entry at $164 today. Our base case supports ~$125–$145; the market is already underwriting much of the 2027 margin/FCF plan and a benign path for remaining legal cash outflows. (investors.3m.com)
- What could prove us too conservative
- Faster delivery on the ~25% margin target and >100% FCF conversion; quicker disposition of the remaining Solventum stake; further portfolio pruning. (investors.3m.com)
- What could disappoint
- Macro softness in electronics/industrial demand; tariff/FX friction bigger than planned; any adverse PFAS/earplug developments or slower insurance recovery. (marketwatch.com)
Suggested action plan
- Accumulate on pullbacks into ~$130–$140 where the margin of safety vs. base DCF improves; trim above ~$170 unless execution clearly outpaces the 2027 roadmap. This range is tied to our DCF/comps outcomes and current 10‑year yields (4.26%). (investors.3m.com)
5) Valuation “audit trail” — sources used
- Results, guidance, and margins (2024–2026): quarterly and annual press releases and news center. (investors.3m.com)
- Investor Day medium‑term targets (growth, ~25% operating margin). (investors.3m.com)
- Cash flow and capex cadence (’25–’26). (investors.3m.com)
- Net debt, cash, and Solventum stake detail (3M 10‑Q, Sep 30, 2025). (investors.3m.com)
- PFAS settlement (PWS) approval and PFAS exit timeline. (investors.3m.com)
- Earplug settlement amounts/timing and insurance recovery efforts. (investors.3m.com)
- Tariff playbook / 2025–2026 performance context. (marketwatch.com)
- Peer multiples snapshots (EV/EBITDA). (valueinvesting.io)
- Risk‑free rate (U.S. 10‑year). (investors.3m.com)
- Current price (Feb 5, 2026, intraday).
6) How we modeled (for transparency)
- Revenue growth is tied to company guidance for 2026 and a modest 3% thereafter—below typical mid‑cycle industrial assumptions. (investors.3m.com)
- Margin path ramps to ~25% by 2027, consistent with Investor Day framing; we keep it near that level rather than extrapolating higher. (investors.3m.com)
- D&A and capex are based on filings and guidance (D&A ≈$1.1–$1.25B; capex ≈$1.1B), and we model neutral working capital over the full period. (investors.3m.com)
- WACC is constructed from an observed 10‑year of 4.26%, typical large‑cap industrial beta, 5.5% equity risk premium, and a BBB+/A− credit cost, yielding ~9% base. (investors.3m.com)
- We stress‑tested the model across WACC 8%–10.5% and terminal growth 1.5%–2.5% to produce the range shown.
Bottom line: 3M’s fundamentals are moving in the right direction and legacy risks are far better quantified, but the stock already prices in much of the improvement. For a value entry, be patient and let price come to you.
Disclaimer: This independent analysis is for informational/educational purposes only and is not investment advice. All models rely on public sources cited above; do your own research and consider your objectives and risk tolerance.